JPH04634B2 - - Google Patents
Info
- Publication number
- JPH04634B2 JPH04634B2 JP58237636A JP23763683A JPH04634B2 JP H04634 B2 JPH04634 B2 JP H04634B2 JP 58237636 A JP58237636 A JP 58237636A JP 23763683 A JP23763683 A JP 23763683A JP H04634 B2 JPH04634 B2 JP H04634B2
- Authority
- JP
- Japan
- Prior art keywords
- urokinase
- antibody
- specific activity
- purified
- immobilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 claims description 27
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 229940088598 enzyme Drugs 0.000 claims description 20
- 229960005356 urokinase Drugs 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 13
- 230000000890 antigenic effect Effects 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 10
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 10
- 102000004452 Arginase Human genes 0.000 claims description 6
- 108700024123 Arginases Proteins 0.000 claims description 6
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 229940012957 plasmin Drugs 0.000 claims description 5
- 108010088842 Fibrinolysin Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 230000002414 glycolytic effect Effects 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 229960001322 trypsin Drugs 0.000 claims description 4
- 239000004382 Amylase Substances 0.000 claims description 3
- 108010065511 Amylases Proteins 0.000 claims description 3
- 102000013142 Amylases Human genes 0.000 claims description 3
- 235000019418 amylase Nutrition 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 17
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 15
- 238000011084 recovery Methods 0.000 description 13
- 229920002684 Sepharose Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 230000035931 haemagglutination Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 108010019077 beta-Amylase Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- -1 Hyflo Super Cell Chemical compound 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58237636A JPS60130526A (ja) | 1983-12-15 | 1983-12-15 | 抗原物質の精製方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58237636A JPS60130526A (ja) | 1983-12-15 | 1983-12-15 | 抗原物質の精製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60130526A JPS60130526A (ja) | 1985-07-12 |
| JPH04634B2 true JPH04634B2 (en, 2012) | 1992-01-08 |
Family
ID=17018259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58237636A Granted JPS60130526A (ja) | 1983-12-15 | 1983-12-15 | 抗原物質の精製方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60130526A (en, 2012) |
-
1983
- 1983-12-15 JP JP58237636A patent/JPS60130526A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60130526A (ja) | 1985-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5733742A (en) | Production of antibody fragments from whole blood | |
| US5580962A (en) | Parenterally administrable drug having thrombolytic activity and containing protein C | |
| US4075193A (en) | Process for producing intravenous immune globulin | |
| US4381346A (en) | Isolation of plasminogen activators useful as therapeutic and diagnostic agents | |
| EP0011032B1 (en) | Method for isolation of hbsag | |
| JP2651307B2 (ja) | 血液凝固ｉｘ因子を含有する複合体 | |
| US4380511A (en) | Purification of bovine thrombin | |
| AU658881B2 (en) | Use of protein C or activated protein C | |
| AU606582B2 (en) | Methods for the recovery of tissue plasminogen activator | |
| JPS6136811B2 (en, 2012) | ||
| JPH0574576B2 (en, 2012) | ||
| JPH07126183A (ja) | ビタミンｋ依存性タンパク質を含有する治療用途に適した薬剤的組成物 | |
| USRE32271E (en) | Isolation of plasminogen activators useful as therapeutic and diagnostic agents | |
| CA1288711C (en) | Therapeutic blood product means and methods of preparing same | |
| JPH04634B2 (en, 2012) | ||
| US3819605A (en) | Anticoagulant isolation from pit viper using a modified agarose bed and eluting with a benzamidine solution | |
| EP0098123B1 (en) | A process for concentrating and purifying human urinary kallikrein | |
| JPH05170665A (ja) | 血栓溶解活性物質を含有する医薬調製物 | |
| SU1419717A1 (ru) | Способ получени биоспецифических адсорбентов дл выделени фибронектина и коллагеназ | |
| JPS61103895A (ja) | ＨＢｓＡｇの精製方法 | |
| CA1333163C (en) | Methods for the recovery of tissue plasminogen activator | |
| JP2714817B2 (ja) | ウロキナーゼ前駆体の製造方法 | |
| JPS6141548B2 (en, 2012) | ||
| US3884760A (en) | Production of urokinase | |
| WO1991013976A1 (en) | Process for producing purified tissue plasminogen activator or its derivative |